Drug Profile
Autologous chondrocyte implantation - Ocugen
Alternative Names: MDNT01; NeoCartLatest Information Update: 05 Oct 2023
Price :
$50
*
At a glance
- Originator Histogenics Corporation
- Developer Histogenics Corporation; Ocugen
- Class Cell therapies
- Mechanism of Action Chondrocytes replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Cartilage disorders
Most Recent Events
- 04 Oct 2023 Ocugen plans a phase III trial for Cartilage disorders in USA in the second half of 2024
- 16 Dec 2022 Ocugen announces intention to file phase III IND application to US FDA for Cartilage disorders in late 2023 or early 2024
- 24 May 2022 Autologous chondrocyte implantation - Ocugen receives Regenerative Medicine Advanced Therapy (RMAT) status for Cartilage disorders (In adults) in USA